Search

Scientific Record

• 6113 life time citations, h-index = 45 (Scopus)
• 10,624 life time citations, h-index = 58 (Google Scholar)
• 300+ peer-reviewed publications (222 papers)
• 700+ conference abstracts
• 184 invited presentations
• 67 graduate students and PDFs
• 14 patents and 4 spin-off companies

As an Early Career Researcher (ECR), Dr. Elliott has been involved as Nominated Principal Applicant, co-Principal Applicant or co-Applicant on research funding from tri-council and community grants.

She has more than 35 published papers related to health systems research and patient/family engagement and has been recognized with multiple awards for her conference presentations.

Dr. Elliott is a Scientist with Lawson Research Institute and holds Adjunct Assistant Professor appointments at Western University (Faculty of Health Sciences) and the University of Waterloo (School of Public Health Sciences).

Currently, Dr. Elliott is the Director, Research & Strategy for the Regional Geriatric Program of Southwestern Ontario, hosted by St. Joseph's Health Care London.

Dr. Alexandre Legros is a full time scientist in the Imaging Program at Lawson, where he is the director of Human Threshold Research Group and Testing Facility. He is also an Associate Professor in the Departments of Medical Biophysics and Medical Imaging within the Schulich School of Medicine and Dentistry, and in the School of Kinesiology from within the Faculty of Health Sciences at Western University.

He received his PhD in Kinesiology in 2004 (University of Montpellier, France) and completed a first postdoctoral fellowship in neuroscience studying the impact of Deep Brain electric Stimulation (DBS) on patients implanted with electrodes suffering from dystonic syndromes (Neurosurgical Unit, University of Montpellier, France). He started a second postdoctoral fellowship in the BEMS group at Lawson in 2005 before being recruited as a young scientist in September 2007.

Dr. Legros has expertise in the fields of neuroscience, kinesiology, biophysics, and he his currently promoting the use of mathematical neuroscience to study the interaction between time-varying magnetic fields and neuronal assemblies/networks.

Dr. Wisenberg is a cardiologist at London Health Sciences Centre, who was trained in the seminal days of nuclear cardiology. He participated in the early human trials at UCLA assessing the role of PET in assessing regional myocardial perfusion. His career has involved the use of a number of imaging modalities including SPECT, PET, MRI, and CT with specific reference to their role in assessing response to therapy and in guiding the management of cardiac patients. His current research focus is on determining the optimum time to inject stem cells to maximize the likelihood for myocardial regeneration, and to improve means of prolonging the residence time of the stem cells in the heart so that they can exert the greatest degree of repair.

As Director of the Lawson Cyclotron and PET Radiochemistry Facility, I lead a self-funded, multi-faceted clinical research program by producing Positron Emitting Radiopharmaceuticals (PERs) for clinical imaging procedures and to support our clinical and pre-clinical PET imaging research programs. As a Scientist working within a hospital setting, our research program has become adept at translating PERs truly from bench to bedside. Our facility holds a Health Canada Establishment License which certifies that we are GMP compliant, and permitted to manufacture and distribute PERs throughout Southern Ontario. In addition to holding our own market authorization for [¹⁸F]FDG, we were the first site (of 2 currently) in Canada to produce Florbetapir and Flortaucapir as a contract manufacture for Avid Radiopharmaceuticals Inc. for Alzheimer’s Disease imaging with PET. In addition, we currently support a number of clinical PET imaging studies with the PERs [¹⁸]FEPPA (neuro inflammation), [¹⁸F]sodium fluoride (bone imaging), [¹³N]ammonia (myocardial perfusion imaging), [¹⁵O]water (perfusion imaging). We produce a larger number of PERs for preclinical use such as [¹¹C]HED, [¹¹C]PHNO, [¹¹C]DTBZ, [¹⁵O]Oxygen gas, and many more. Since opening in 2010, we have demonstrated excellent competency of developing new PERs, getting them into preclinical imaging models, and ultimately translating them into clinical studies in human subjects.

My research program is focused on radionuclide production utilizing solid phase cyclotron targets. We have developed a high current, solid phase target system for the GE PETtrace cyclotron that includes automated target transfer, dissolution, and separation chemistry in a GMP compliant manner for [^99mTc]NaTcO₄. With the clinical trials data we collected from a total of 60 patients on two different sites, we are in the process of submitting a New Drug Submission to Health Canada for market authorization of cyclotron produced pertechnetate. This project, along with our partners in Hamilton ON and Vancouver BC, was awarded the Brockhouse Prize by the Governor General in 2015 for the best interdisciplinary research collaboration in the Canada. Our current efforts are focused on expanding the utility of this target system, in particular the production of the PET radiometals ⁶⁸Ga and ⁸⁹Zr.